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Background: Compartmental analysis is a standard method to quantify metabolic processes using
fluorodeoxyglucose-positron emission tomography (FDG-PET). For liver studies, this analysis is complex due to
the hepatocyte capability to dephosphorylate and release glucose and FDG into the blood. Moreover, a tracer is
supplied to the liver by both the hepatic artery and the portal vein, which is not visible in PET images. This study
developed an innovative computational approach accounting for the reversible nature of FDG in the liver and
directly computing the portal vein tracer concentration by means of gut radioactivity measurements.
Methods: Twenty-one mice were subdivided into three groups: the control group ‘CTR’ (n = 7) received no treatment,
the short-term starvation group ‘STS’ (n = 7) was submitted to food deprivation with free access to water within 48 h
before imaging, and the metformin group ‘MTF’ (n = 7) was treated with metformin (750 mg/Kg per day) for 1 month.
All mice underwent a dynamic micro-PET study for 50 min after an 18F-FDG injection. The compartmental analysis
considered two FDG pools (phosphorylated and free) in both the gut and liver. A tracer was carried into the liver by
the hepatic artery and the portal vein, and tracer delivery from the gut was considered as the sole input for portal vein
tracer concentration. Accordingly, both the liver and gut were characterized by two compartments and two exchange
coefficients. Each one of the two two-compartment models was mathematically described by a system of differential
equations, and data optimization was performed by applying a Newton algorithm to the inverse problems associated
to these differential systems.
Results: All rate constants were stable in each group. The tracer coefficient from the free to the metabolized
compartment in the liver was increased by STS, while it was unaltered by MTF. By contrast, the tracer coefficient from
the metabolized to the free compartment was reduced by MTF and increased by STS.
Conclusions: Data demonstrated that our method was able to analyze FDG kinetics under pharmacological or
pathophysiological stimulation, quantifying the fraction of the tracer trapped in the liver or dephosphorylated and
released into the bloodstream.
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Figure 1 Compartmental model for the gut and liver. The ‘portal
vein’ compartment utilizes kpg to compute Cp.
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Hepatic glucose metabolism is of relevance in a number of
clinical syndromes and, in particular, in diabetes [1-5]. Sev-
eral authors previously evaluated the potential of positron
emission tomography (PET) with 18F-fluorodeoxyglucose
(FDG) in this setting, both in humans and animals [2,3].
However, a standard method has not been developed so
far because of the peculiarities of liver function and anat-
omy. From the physiological viewpoint, hepatocytes can
dephosphorylate glucose-6-phosphate (G6P) to deliver
glucose back into the bloodstream. This feature also
applies to FDG-6-phosphate (FDG-6P) preventing the
accumulation kinetics typical of most tissues and nicely
suited to compartmental analysis. From the anatomical
viewpoint, the dual blood supply from the hepatic artery
(HA) and portal vein (PV) further hampers the definition
of tracer delivery to hepatic tissue [6]. Actually, limiting
the analysis to the arterial input function (IF) inevitably
causes systematic underestimation of tracer distribution
in the liver [7-11]. Accordingly, several attempts have
been made to estimate the dual-input IFs from dynamic
PET data [8,12,13]. However, no method successfully
solved this problem so far, since the PV is hard to
recognize in PET images and suffers from a relevant
partial-volume effect related to vessel size and respira-
tory movements.
According to these limitations, several authors tried to
indirectly predict the PV tracer concentration by the
arterial IF. More precisely, one approach applied ad hoc
algorithms to compute the PV IF as a heuristic modifica-
tion of the arterial one [5,9]. A second approach directly
and invasively sampled the PV IF [3-5] and then deter-
mined the dual IF as a weighed superposition of the two
activities [10,14-18]. However, both methods are model-
dependent and difficult to apply in a noninvasive setting,
while their potential under non-physiological conditions
has been scarcely explored.
To overcome these limitations, we coupled the cap-
ability of micro-PET to provide FDG time activity curves
(TACs) in virtually all organs with the formulation of a
novel compartmental model (see Figure 1) for the hep-
atic system using the following three descriptors of
tracer kinetics in the liver:
1. The time-concentration curve in the arterial system.
2. The time-concentration curve in the liver.
3. The time-concentration curve in the whole gut as
the source of the PV blood.
We used this information as input data of an iterative
algorithm [19] that reduces a compartmental model in
which gut tracer concentration is used to compute the
PV IF, while liver activity is used to describe tracer kin-
etics in the hepatic system. In the present study, weaimed at validating this algorithm by testing its per-
formance in mice treated with interventions able to
blunt or enhance liver G6P dephosphorylation and glu-
cose delivery.Methods
Reagents
Metformin was provided by Sigma-Aldrich (St. Louis,
MO, USA). FDG was produced in-house, according to
standard methodology. Daily quality controls always
documented adequate standards and, in particular, a
radiochemical purity ≥98%.Animal models
All animal experiments were reviewed and approved by
the Licensing and Ethical Committee of the IRCCS San
Martino IST, Genova, Italy, and by the Italian Ministero
della Salute. A total of 21 six-week-old BALB/c female
mice (Charles River Laboratories, Italy) were housed
under specific pathogen-free conditions and subdivided
into three different groups according to the treatment
preceding the imaging study. The first group of controls
(CTR) included seven untreated animals that did not
receive any treatment and were kept under standard
conditions for the whole study duration. The short-term
starvation group (STS) included seven mice that were
submitted to food deprivation with free access to water
within 48 h before imaging. Finally, the last group
(MTF) included seven mice treated with metformin for
the month preceding the imaging test. In these animals,
the drug was administered diluted in autoclaved drinking
water at a concentration of 3 mg/mL as to account for a
dose of 750 mg/Kg per day [11].
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In vivo imaging was performed according to a protocol
validated in our lab [11]. To ensure a steady state of sub-
strate and hormones governing glucose metabolism, all
animals were studied after 6 h of fasting. Mice were
weighed, and anesthesia was induced by intraperitoneal
administration of ketamine/xylazine (100 and 10 mg/Kg,
respectively). Serum glucose level was measured, and
animals were positioned on the bed of a dedicated
micro-PET system (Albira, Bruker, USA) whose two-ring
configuration permits to cover the whole animal body in
a single bed position. A dose of 3 to 4 MBq of FDG was
then injected through a tail vein, soon after the start of a
list mode acquisition lasting 50 min. Acquisition was re-
constructed using the following framing rate: 10 × 15 s,
5 × 30 s, 2 × 150 s, 6 × 300 s, and 1 × 600 s. PET data
were reconstructed using a maximum likelihood expect-
ation maximization (MLEM) method. Thereafter, each
image dataset was reviewed by an experienced observer
who recognized three regions of interest (ROIs) encom-
passing the aortic arc, gut, and liver, respectively (seeFigure 2 Typical ROIs and TACs of the aortic arc (white), gut (green), and lFigure 2). The same figure also shows the TACs com-
puted from the three ROIs in the case of animals be-
longing to the analyzed groups (CTR, STS, MTF). We
are aware that the determination of the arterial IF is a
challenging task in the case of mice. To accomplish it,
for each animal model, we have first viewed the tracer
first pass in cine mode. Then, in a frame where the left
ventricle was particularly visible, we have drawn a ROI
in the aortic arc and maintained it for all time points.
Therefore, in this study, we used the resulting TAC as
arterial IF. We recognize that this procedure may be af-
fected by partial volume effects in the PET data; how-
ever, we expect this kind of error to be systematic for all
datasets and therefore to affect the results in a way
which is essentially independent of the experiment. Cine
mode representation was used also to obtain the gut
and liver TACs, since especially kidneys and bladder
often display a biphasic curve due to tracer filtration-
accumulation and possible voiding preventing their rec-
ognition in the last frame. For example, in the gut case,
a ROI was drawn analyzing in cine mode all 27 frames ofiver (red).
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μL and were placed systematically in the anterior abdo-
men, paying care to exclude contamination from the liver,
spleen, kidney, and large vessels throughout all frames.
Compartmental modeling of FDG kinetics
Our approach for the definition of the dual IF was based
on processing a complete set of ROIs drawn on the aortic
arc, gut, and liver. In particular, we aimed to describe the
gut by means of a compartmental model with one arterial
IF and one output directly delivering the tracer in the PV
blood. This latter concentration was then used as the ven-
ous IF in a second compartmental model focused on the
liver. Since both the gut and liver express G-6P-
phosphatase, they were described by means of two func-
tional compartments that account for the significant
exchange between trapped and free tracer, i.e., between
FDG-6P and FDG. This compartmental system is de-
scribed in Figure 1.
Gut subsystem
This subsystem was considered to have one arterial IF,
one output function to the PV, and two compartments:
the free tracer in the gut (denoted with g) and the
trapped FDG-6P (denoted with t). The mathematical
model at the basis of our compartmental analysis relied
on the balance of the tracer activities (i.e., concentrations
per unit volume) between the different compartments.
This balance leads to a number of ordinary differential
equations, which are a standard in this framework. In the
specific case of the gut tracer kinetics, the compartmental
model is made of the following two differential equations
with vanishing initial data:
_Cg ¼ −ðktg þ kpgÞCg þ kgtCt þ kgaCa ð1Þ
_Ct ¼ ktgCg−kgtCt : ð2Þ
In these equations, Cg, Ct, and Ca represent the tracer
concentrations in the free compartment g, in the phos-
phorylated compartment t, and in the arterial blood a,
respectively; the superposed dot indicates differentiation
with respect to time, and the coefficients kij (measured
in min−1) denote the rate coefficients to the target com-
partment i from the source compartment j. Equations
(1) and (2) can be formally solved to obtain the analyt-
ical expressions of Cg and Ct. We observe that such ex-
pressions depend on the tracer coefficients that at this
stage of the solution process are still unknown.
In order to describe the output of the gut subsystem, we
introduced a further compartment p, anatomically repre-
sented by the PV. Assuming that in such a compartment
the blood flow is constant (which implies kpg = kfp),activity conservation leads to a third differential equation
for the concentration Cp:
_Cp ¼ kpgCg−kpgCp: ð3Þ
Also, in the case of Equation (3), the analytical solution
can be formally determined and depends on the kinetics
parameter kpg.
Liver subsystem
According to standard results [17], also the liver can be
described as a two-compartment model, one consisting
of non-metabolized, free, tracer (compartment f ), and
one consisting of phosphorylated, metabolized tracer
(compartment m), where, as in the case of the gut,
dephosphorylation is explicitly allowed. Tracer inputs
through the HA and PV (compartments a and p, re-
spectively) are modeled in an independent manner, i.e.,
there is no mixing of blood from the two vessels before
entrance into the liver. On the contrary, possible hetero-
geneities in perfusion source may occur as to consider
the most general input model. Accordingly, exchange
coefficients for the HA blood (kfa) and the PV blood
(kfp) are considered as independent. On the other hand,
FDG delivery to the PV blood is considered to occur
only from the gut, tracer exchange throughout the vein
is negligible, and thus, the whole tracer amount entered
into the PV is available for liver uptake.
We now denote with Cf and Cm the concentration of
the free and metabolized FDG pools, respectively, with
ksf the rate coefficient from the free compartment to the
venous efflux to the suprahepatic vein s, kmf the ex-
change coefficient from the FDG to the FDG-6P pool,
and kfm the exchange coefficient for the inverse process.
Then, the usual assumption on the conservation of ac-
tivities provides:
_Cf ¼ − kmf þ ksf
 
Cf þ kfmCmþmkf aCa þ kpgCp ð4Þ
and
_Cm ¼ kmf Cf −kfmCm: ð5Þ
Equations (4) and (5) can be again formally solved to
obtain the analytical expressions of Cf and Cm. We ob-
serve again that such expressions depend on the tracer
coefficients that at this stage of the solution process are
still unknown.
Data optimization
Micro-PET data provide information on the overall con-
centrations in ROIs drawn on the gut and liver throughout
the whole acquisition. Therefore, denoting with ~C gut and
~C liver such experimental concentrations, we can write the
following two equations for the micro-PET data:
Table 1 Means and standard deviations for weight,
glycemia, and SUV over the three sets
Weight (g) Glycemia (mg/dl) SUV gut SUV liver
CTR 24.4 ± 1.8 131.1 ± 12.1 1.07 ± 0.36 1.07 ± 0.33
MTF 23.9 ± 1.3 89.1 ± 18.6 2.49 ± 0.97 1.03 ± 0.31
STS 23.7 ± 1.6 54.0 ± 24.3 1.51 ± 0.39 1.17 ± 0.27
SUV data have been measured at the last experimental frame.
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~C liver−V 0:11Ca þ 0:89Cp
  ¼ 1−Vð Þ Cf þ Cm
  ð7Þ
where the numerical coefficients 0.11 and 0.89 indicate
the rate of arterial and venous contributions to the hep-
atic blood content V per unit volume [8,17]. Further, we
assumed for V the physiologically sound value of 0.3 [9].
In principle, these values may change between the differ-
ent groups; therefore, we made the same computation
for different pairs of values (0.15 to 0.85, 0.25 to 0.75,
0.5 to 0.5, respectively). The mean values of the tracer
coefficients did not change significantly while the corre-
sponding uncertainties increased with respect to the
choice 0.11 to 0.89.
In order to numerically solve Equations (6) and (7)
and therefore to determine the tracer coefficients, we
applied, separately and in cascade, a regularized multi-
dimensional Newton algorithm [19], where a nice trade-
off between the numerical stability of the problem solu-
tion and an appropriate fitting of the measured data
were obtained by means of an optimized selection of the
regularization parameter. To this aim, we first observed
using simulations that the regularized Newton algorithm
is rather robust with respect to the choice of the
regularization parameter. In fact, in the case of a synthetic
dataset, there exists a unique value of the regularization
parameter that minimizes the distance between the recon-
structed and ground-truth tracer coefficient vector. For all
simulations performed, this value had an order of magni-
tude of around 104, and tuning such value in the range of
103 to 105 changed the reconstructed coefficients of less
than 0.5%. In the case of experimental data, for each
mouse, we applied a discrepancy approach: we chose as
optimal value of the regularization parameter the value for
which the discrepancy between the experimental data and
the data predicted by the regularized solution coincided
with the uncertainty on the measurement [20]. This un-
certainty was computed by assuming that the noise on the
activity is Poisson and the values of the regularization par-
ameter we obtained were around 104, as in the simulated
cases. We are aware that the Poisson assumption on the
uncertainty does not account for correlation and other ef-
fects induced by the reconstruction algorithm; however,
the robustness of regularization guarantees for the reliabil-
ity of this approach.
From a computational viewpoint, the codes imple-
menting the reduction of these compartmental models
are extremely fast (less than 1 min for each analysis).
Further, in order to assess the numerical robustness of
the approach, for each animal model we have perturbed
50 times the PV TAC (obtained from the reduction of
the gut subsystem) with 50 different Poisson random
components, and accordingly, we have computed thetracer coefficients for the liver. For each coefficient, the
standard deviation corresponding to the mean value over
the several runs of the algorithm represents a reliable
measure of the robustness of the approach with respect
to uncertainties in the computation of the PV TAC. We




The experiments were completed in all animals, and no
side effects occurred at the drug dosage used. Body
weight was stable, and glycemia was reduced only in the
STS mice (Table 1). In agreement with our previous ex-
perience [21], the response of whole body glucose me-
tabolism was characterized by a relative reduction in
FDG clearance and whole body glucose consumption in
both MTF and STS animals. Similarly [11], this systemic
effect was paralleled by a peculiar response of tracer dis-
tribution in the different investigated organs. In fact,
MTF treatment was followed by an increase in gut tracer
retention and thus in higher gut average standardized
uptake value (SUV) with respect to control (2.49 ± 0.97
vs 1.07 ± 0.36, p < 0.01 vs CTR). On the contrary, liver
FDG accumulation was eventually similar, independently
of experimental conditions (Table 1).
Estimation of the PV TAC
While in each animal the arterial TAC was obtained
experimentally, the TAC in the PV was the result of
the computational analysis. More precisely, we solved
Equation (3) and sampled the time range according
to typical acquisition times for ‘Albira’ (10 × 15 s, 5 ×
30 s, 2 × 150 s, 6 × 300 s, 1 × 600 s). This curve (see
Figure 3) well fitted with expectations based on previous
literature [6,8].
Effects on liver FDG kinetics
In our compartmental analysis, rate constants of FDG
handling in the liver were indicated as kmf and kfm; they
represent, respectively, the exchange coefficients from
the free compartment to the phosphorylated one and its
reciprocal. According to the values given in Table 2 and
Figure 4, kmf in the liver was left virtually unaltered by
MTF (0.004 ± 0.003 min−1, p = ns vs CTR), while it was
Figure 3 Comparison between the HA and PV tracer concentrations
in one mice.
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vs the CTR and MTF group), as expected as a conse-
quence of the fasting condition.
The rate coefficient kfm describes dephosphorylation
of FDG-6-P inside the liver. According to Table 2 and
Figure 5, this process was markedly reduced by MTF
(0.041 ± 0.026 min−1 vs 0.154 ± 0.059 min−1, p < 0.01 vs
CTR). On the contrary, kfm was increased by STS to
0.5632 ± 0.221 min−1 (p < 0.01 vs CTR). This last result
gives evidence to the occurrence of an increase of this
coefficient, expressing the rate exchange between the
metabolized and the free compartment, as a natural
consequence of a significant caloric restriction.
We further observe that a Patlak analysis of the same
data did not allow us to differentiate the three groups,
since we found statistically comparable Patlak slopes
(1.09 ± 0.11 for CTR, 1.08 ± 0.12 for MTF, and 1.11 ±
0.24 for STS). Table 2 also reports an increase of ksf
(3.801 ± 1.650 min−1 vs 2.51 ± 0.51 min−1, p = 0.07 vs
CTR) and an increase of kfa in the STS models (2.384 ±
0.689 min−1 vs 2.180 ± 0.568 min−1, p = 0.07 vs CTR),
which corresponds to a significant release of FDG from
the mice liver to the bloodstream and a less significant
input increase from the blood to the liver, induced by
starvation. The effect of MTF treatment on these coeffi-
cients was negligible.
Finally, no statistically significant change in the values
of kfp for the three groups was observed.Table 2 Means and standard deviations for the gut and liver
kfa kmf ksf kfm
CTR 2.180 ± 0.568 0.003 ± 0.003 2.51 ± 0.51 0.154 ± 0.059
MTF 2.112 ± 0.420 0.004 ± 0.003 2.478 ± 0.389 0.041 ± 0.026
STS 2.384 ± 0.689 0.095 ± 0.051* 3.801 ± 1.650 0.563 ± 0.221
With *, we indicate all comparisons with p < 0.05; with **, all comparisons with p <Discussion
This study introduces a computation-based, model-
dependent method for the use of FDG to study glucose
kinetics in the liver. The main advantage and novelty of
this approach are that it is able to determine the dual in-
put typical of liver physiology just by means of computa-
tion, thus avoiding: 1) the use of invasive catheter-based
measurement procedures and 2) the major drawback of
methods relying on the sole arterial IF, which are not
able to account for the intrinsic variability of perfusion
and glucose consumption in splanchnic organs. Other
attempts to compute the PV IF have been performed
([8] and references within), but those cases rely on a
heuristic modification of the arterial IF which is obtained
once for all and applied to all animal models. On the
contrary, our method is intrinsically model-dependent,
since it utilizes compartmental analysis of the gut to dir-
ectly estimate the PV IF, which, in its turn, is combined
with the arterial TAC (obtained via ROIs on the aortic
arc) to perform the compartmental analysis of the liver.
From a numerical viewpoint, this task was accomplished
applying the regularized Newton algorithm to the in-
verse problems associated to the multi-dimensional Cau-
chy problems describing the two-compartment gut and
liver systems, respectively. In this setting, the computa-
tion of this algorithm, which is rather similar to other
optimization algorithms applied in compartmental ana-
lysis [22-25], is rather effective, since the matrix differen-
tiation step required at some stage can be realized
analytically, thus, avoiding time consuming numerical
differentiation. The advantages of this technique are the
ability to correctly identify the response of rate constants
to experimental interventions able to modify hepatic
glucose metabolism and a notable robustness with re-
spect to data optimization. The robustness of the
method has been tested by computing the tracer coeffi-
cients for the liver in the case of different perturbed
values of the PV TAC for each animal model. The corre-
sponding standard deviations were always below 4% of
the mean values, showing the notable numerical robust-
ness of the numerical process.
Pathophysiological considerations
The liver plays a crucial role in the maintenance of gly-
cemic levels despite a large variability in glucose con-
sumption in the different body tissues. To this purpose,kinetics parameters over the three sets
kfp kga ktg kgt
2.291 ± 0.530 1.109 ± 0.331 0.036 ± 0.029 0.047 ± 0.029
** 2.068 ± 0.757 0.902 ± 0.305 0.118 ± 0.073 0.029 ± 0.012
** 2.135 ± 0.646 0.963 ± 0.373 0.060 ± 0.008 0.181 ± 0.10
0.01. All the kij are measured in min
−1.
Figure 4 Comparison between the values of kmf in the metabolized and the free compartment. Each bar represents the mean over a specific set
of mice, while the black line represents standard deviation.
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hyperglycemic response to food intake and to adapt
serum glucose concentration to whole body needs under
fasting periods. This buffer function is of pivotal import-
ance since - once entered in the cytosol of almost all
mammalian cells - glucose is sequestered by its phosphor-
ylation to G6P. The irreversible nature of this reaction also
applies to FDG whose accumulation as FDG-6P accounts
for the potential of this tracer in the study of brain and
tumor metabolism [26].
Coherently with its role in maintaining metabolic
homeostasis, this simplified model does not apply to he-
patocytes whose G6P content - either newly synthetized
or coming from glycogen breakdown - can be hydro-
lyzed to Pi and glucose by G6Pase. This reaction replen-
ishes cytosol content of glucose to be released into the
bloodstream. In agreement with this homeostatic role,
liver G6Pase catalytic function is downregulated by insu-
lin response to feeding [12] while it is markedlyFigure 5 Comparison between the values of kfm in the metabolized and th
of mice, while the black line represents standard deviation.enhanced by the high glucagon levels occurring during
fasting periods [13].
Our results favorably compared with this well-
validated biochemical model. In the present study, effect
of feeding was not tested, as this condition abolishes the
steady-state of serum glucose and insulin needed for an
accurate compartmental analysis of liver metabolism.
Nevertheless, STS increased rate constant kfm (as an
index of FDG-6P dephosphorylation to FDG) about
threefold with respect to 6 h of fasting, indicating a reli-
ability of our measurements.
This finding was confirmed by the data obtained under
the opposite condition. To this purpose, we studied ani-
mals exposed to prolonged treatment with high doses of
MTF, the most widely used drug in the treatment of type
2 diabetes. MTF exerts its anti-hyperglycemic effect
mainly decreasing hepatic gluconeogenesis via AMP-
dependent protein kinase (AMPK) activation through
the upstream kinase liver kinase B1 (LKB1) [7]. Moree free compartment. Each bar represents the mean over a specific set
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or even silences the expression of all gluconeogenic en-
zymes and mostly of G6Pase [27]. Again, our approach
to liver FDG kinetics nicely agreed with this mechanism
of action. In fact, treatment with high MTF doses pro-
foundly reduced kfm values, indicating a reduced rate of
G6P hydrolysis as expected on the basis of a reduced
G6Pase abundance. In this line, our data extend previous
studies documenting an increase in hepatic glucose up-
take under MTF treatment in subjects with type 2 dia-
betes [3-5]. This finding has been usually attributed to a
direct increase in glucokinase function induced by the
improved metabolic control. Our data indicate that, be-
sides the enhancement in retention mechanism, MTF
also decreases glucose and FDG output by inhibiting
G6Pase activity. Even more interestingly, the response of
kfm to both STS and MTF was paralleled by a relative in-
variance of kfp and ksf in the three mice groups analyzed,
demonstrating a similar blood input (PV) and output
(SV) in the liver vein system.
Interestingly, in STS models, the value of the rate con-
stant from arterial blood to the liver free compartment
(kfa) was increased, probably due to the low glucose con-
centration in the blood during caloric restriction and the
consequent increased demand by the liver.
Conclusions
In conclusion, our data demonstrated the effectiveness of
an innovative computational method to analyze the liver
FDG kinetics under pharmacological or pathophysiological
stimuli. Although we used a rather complex compartmen-
tal model characterized by nine unknowns, the regularized
Newton algorithm was able to estimate all unknowns with
a satisfactory degree of robustness. This permitted to
quantify the fraction of tracer trapped in the liver or
dephosphorylated and released into the bloodstream
and thus conveyed to the different tissues.
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